Naples Global Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 7.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,572 shares of the company’s stock after purchasing an additional 1,433 shares during the period. Johnson & Johnson comprises 0.8% of Naples Global Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Naples Global Advisors LLC’s holdings in Johnson & Johnson were worth $2,874,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Harding Loevner LP purchased a new position in Johnson & Johnson during the second quarter worth $106,000. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the second quarter worth $124,000. Lenox Wealth Management Inc. increased its position in Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares in the last quarter. Intercontinental Wealth Advisors LLC purchased a new position in Johnson & Johnson during the second quarter worth $200,000. Finally, Legacy Advisors LLC purchased a new position in Johnson & Johnson during the third quarter worth $202,000. 67.23% of the stock is owned by hedge funds and other institutional investors.
In related news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.22% of the stock is currently owned by company insiders.
Shares of Johnson & Johnson stock opened at $128.10 on Friday. Johnson & Johnson has a twelve month low of $120.95 and a twelve month high of $148.32. The firm has a market capitalization of $349,877.28, a P/E ratio of 17.55, a PEG ratio of 2.07 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3337560/johnson-johnson-jnj-shares-bought-by-naples-global-advisors-llc.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.